Article Information
PubMed
Published By
History
- Received August 23, 2015
- Revision received September 15, 2015
- Accepted September 24, 2015
- First published November 18, 2015.
- Version of record published November 18, 2015.
Copyright & Usage
Copyright © 2015 the authors 0270-6474/15/3515403-16$15.00/0
Author Information
Author contributions
↵*S.M.S. and W.B.J.C. contributed equally to this work.
Disclosures
- Received August 23, 2015.
- Revision received September 15, 2015.
- Accepted September 24, 2015.
Author contributions: K.L.F., S.M.S., and W.B.J.C. designed research; K.L.F. and W.B.J.C. performed research; K.L.F. and W.B.J.C. analyzed data; K.L.F., S.M.S., and W.B.J.C. wrote the paper.
This work was supported by the National Institutes of Health (Grant R01NS080388 to S.M.S.) and the Falk Medical Research Trust (S.M.S.).
S.M.S. is a cofounder of Axerion Therapeutics, seeking to develop NgR- and PrP-based therapeutics. The remaining authors declare no competing financial interests.
- Correspondence should be addressed to either Stephen M. Strittmatter or William B.J.Cafferty, Department of Neurology and Program in Cellular Neuroscience, Neurodegeneration and Repair, Yale University School of Medicine, 8300F 300 George Street, New Haven, CT 06520, william.cafferty{at}yale.edu or stephen.strittmatter{at}yale.edu
